<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701077</url>
  </required_header>
  <id_info>
    <org_study_id>P060802</org_study_id>
    <secondary_id>EUDRACT 2007-004133-42</secondary_id>
    <nct_id>NCT00701077</nct_id>
  </id_info>
  <brief_title>DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome</brief_title>
  <acronym>DAPREB</acronym>
  <official_title>DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Brugada syndrome is a rare disease potentially leading to severe arrhythmic events in&#xD;
      otherwise healthy subjects.In many patients an Implantable cardiovertor defibrillator (ICD)&#xD;
      is implanted to prevent sudden cardiac death. ICD are however associated with potential&#xD;
      complications and are not available in all countries.Pharmacological blockade of specific ion&#xD;
      channels (Ito) represents a promising therapeutic approach in this syndrome.The&#xD;
      3,4-diaminopyridine (3,4-DAP) is a pharmacological Ito blocker that can be used in humans.The&#xD;
      aim of the study is to evaluate the effect of 3,4-DAP on ventricular arrhythmia inducibility&#xD;
      in Brugada patients requiring an electrophysiological study for arrhythmic risk&#xD;
      stratification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      The Brugada syndrome is a rare disease potentially leading to severe arrhythmic events in&#xD;
      otherwise healthy subjects.In many patients an Implantable cardiovertor defibrillator (ICD)&#xD;
      is implanted to prevent sudden cardiac death. ICD are however associated with potential&#xD;
      complications and are not available in all countries.Pharmacological blockade of specific ion&#xD;
      channels (Ito) represents a promising therapeutic approach in this syndrome. Experimental&#xD;
      data show that increased Ito current may be associated with both the ECG feature and&#xD;
      arrhythmogenic substrate observed in the syndrome. Moreover, Ito blockade reverse the ECG&#xD;
      abnormalities and suppress arrhythmogenicity.The 3,4-diaminopyridine (3,4-DAP) is a&#xD;
      pharmacological Ito blocker that is already used in humans for another indication.&#xD;
&#xD;
      Main objective:&#xD;
&#xD;
      The aim of the study is to evaluate the effect of 3,4-DAP on ventricular arrhythmia&#xD;
      inducibility in Brugada patients requiring an electrophysiological study for arrhythmic risk&#xD;
      stratification.&#xD;
&#xD;
      First end point:&#xD;
&#xD;
      Re-inducibility or non re-inducibility of sustained ventricular arrhythmia during&#xD;
      electrophysiological study on treatment&#xD;
&#xD;
      Tested hypothesis:&#xD;
&#xD;
      The 3,4-DAP decreases the proportion of re-inducibility during the electrophysiological study&#xD;
      with a re-inducibility rate of 80% in the placebo group and 25% in the 3,4-DAP group&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
        -  to assess the effect of 3,4-DAP on ST segment elevation in Brugada patients&#xD;
&#xD;
        -  to describe the relationship between 3,4-DAP plasma concentration measured at 45 minutes&#xD;
           and electrophysiological study result and ST segment elevation&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      2 centres, randomised, double blind, parallel groups, placebo controlledA single dose of 20&#xD;
      mg of 3,4-DAP&#xD;
&#xD;
      Included patients and number of patients:&#xD;
&#xD;
      Included patients will all have a diagnosed Brugada type 1 ECG and will require an&#xD;
      electrophysiological study for arrhythmic risk stratification purpose. Only inducible&#xD;
      patients will be included in the study.Using a classical approach, the hypothesis would be&#xD;
      that 80% of on placebo patients would be re-inducible when only 25% of on drug patients&#xD;
      would. To test such an hypothesis, 32 patients (16 in each group) would have been necessary&#xD;
      (a=5%, b=20%).Provided the essential binary response of the electrophysiological study we&#xD;
      choose a sequential approach in order to get the opportunity stop for success or futility the&#xD;
      inclusions before the end of the study. The maximum number of included patients will then be&#xD;
      42 (21 in each group).&#xD;
&#xD;
      Protocol duration:&#xD;
&#xD;
      Study duration is 48 hours for each patient.The protocol duration is planned for 5 years.&#xD;
&#xD;
      Per protocol procedures:&#xD;
&#xD;
        -  Electrophysiological study with ventricular programmed stimulation performed twice&#xD;
&#xD;
        -  Continuous ECG recording- Blood sampling for 3,4-DAP plasma concentration measurement&#xD;
           Potential implications:If the study hypotheses are confirmed it would then be justified&#xD;
           to design long term efficacy studies in Brugada patients implanted with an ICD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitments issues&#xD;
  </why_stopped>
  <start_date type="Actual">September 12, 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electrophysiological study result (re-inducibility or not) 45 minutes after drug intake</measure>
    <time_frame>45 minutes after drug intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the effect of 3,4-DAP on ST segment elevation in Brugada patients (45 minutes)</measure>
    <time_frame>at 45 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the relationship between 3,4-DAP plasma concentration measured at 45 minutes and electrophysiological study result and ST segment elevation</measure>
    <time_frame>at 45 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Brugada Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3,4-Di-amino-Pyridine : a single 20 mg dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-Di-amino-Pyridine</intervention_name>
    <description>a single 20 mg dosing</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman ≥ 18 years old&#xD;
&#xD;
          -  Brugada syndrome diagnosed with a type 1 ECG either spontaneous or drug-induced&#xD;
&#xD;
          -  Electrophysiological study indicated for arrhythmic risk stratification purpose&#xD;
&#xD;
          -  Inducibility of a sustained ventricular tachycardia (&gt; 30 seconds) or ventricular&#xD;
             fibrillation requiring defibrillation&#xD;
&#xD;
          -  Physical medical examination&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal or familial history of epilepsy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Body weight &gt; 100 kg&#xD;
&#xD;
          -  the need of &gt;1 counter shock for defibrillation&#xD;
&#xD;
          -  Alcohol or cocaine consumption during the protocol&#xD;
&#xD;
          -  Class I (with the exception of local anaesthesia by lidocaine), II, III and IV&#xD;
             antiarrhythmic drugs, antidepressant drugs, ATP dependent potassium channel&#xD;
             activators, sultopride not stopped for &gt; 7 halve-lives&#xD;
&#xD;
          -  No medical insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice EXTRAMIANA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lariboisière University Hospital - Cardiology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lariboisière University Hospital - Cardiology department</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brugada syndrome</keyword>
  <keyword>Electrophysiological study</keyword>
  <keyword>Ion channel blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brugada Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

